19 Jan Risk Assessment Nitrosamine Posted at 15:36h in by rdc_redaktion 0 Comments 0 Likes EMA and edqm ask MAH to evaluate the risk of nitrosamines in marketed synthetic drugs. Risk assessment has to be conducted for drug substance, excipients and drug product. RD&C will assist clients.
Sorry, the comment form is closed at this time.